Table 4.
Certainty in the assessment of efficacy outcomes for anti-calcitonin gene-related peptide monoclonal antibodies for prevention in chronic migraine
| Certainty assessment | Certainty | |||||||
|---|---|---|---|---|---|---|---|---|
| Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ||
| Erenumab | ||||||||
| 70 monthly sc | 1 | RCT | not serious | seriousa | not serious | not serious | none | ⨁⨁⨁◯ MEDIUM |
| 140 monthly sc | 1 | RCT | not serious | seriousa | not serious | not serious | none | ⨁⨁⨁◯ MEDIUM |
| Fremanezumab | ||||||||
| 675 quarterly sc | 1 | RCT | not serious | seriousa | not serious | not serious | none | ⨁⨁⨁◯ MEDIUM |
| 675 ld + 225 quarterly sc (except functional improvement) | 2 | RCT | not serious | not serious | not serious | not serious | none | ⨁⨁⨁⨁ HIGH |
| 675 ld + 225 quarterly sc (functional improvement) | 1 | RCT | not serious | seriousa | not serious | not serious | none | ⨁⨁⨁◯ MEDIUM |
| Galcanezumab | ||||||||
| 240 mg ld + 120 mg monthly sc | 1 | RCT | not serious | seriousa | not serious | not serious | none | ⨁⨁⨁◯ MEDIUM |
| 240 mg monthly sc | 1 | RCT | not serious | seriousa | not serious | not serious | none | ⨁⨁⨁◯ MEDIUM |
aInconsistency because of lack of replication
sc subcutaneous, ld loading dose, RCT randomized controlled trial